Hypersensitivity reaction to abacavir is strongly associated with the presence of the HLA-B*5701 allele. This study was designed to establish the effectiveness of prospective HLA-B*5701 screening to prevent the hypersensitivity reaction to abacavir.
[ hide abstract ]
Prospective screening for HLA-B*57:01 eliminated immunologically confirmed abacavir hypersensitivity reactions (p<0.001) and reduced clinically diagnosed hypersensitivity reactions (p<0.001)
|Prospective screening (n=803)||Standard-of-care (n=847)|
|HLA-B*57:01 patients excluded from abacavir treatment||No screening for HLA-B*57:01|
|3.4% developed clinically diagnosed hypersensitivity||7.8% developed clinically diagnosed hypersensitivity|
|0% developed immunologically-confirmed abacavir hypersensitivity||2.7% developed immunologically-confirmed abacavir hypersensitivity|